7-OH Withdrawal: Symptoms, Timeline and Getting Help

7-OH withdrawal is an opioid-type withdrawal syndrome. Published cases describe anxiety, restlessness, sweating, chills, muscle aches, insomnia, nausea, diarrhoea and strong cravings, starting within hours of the last dose rather than days. Doctors have treated it as they would opioid withdrawal, most often with buprenorphine, and some patients needed more medication than expected.^1,2,3

The evidence is thin: single case reports, one small case series and inferences from kratom and opioid research. No controlled study has followed people through 7-OH withdrawal, so any timeline, including ours, is an informed estimate.

Below: why 7-OH causes dependence, what the case reports found, the likely timeline, what clinicians have used, and what the DEA’s October 2026 notice means for current users. If you need help today, the free, confidential SAMHSA National Helpline is open 24 hours a day on 1-800-662-4357.⁴

At a glance

Question	What the evidence shows
Type of withdrawal	Opioid-like; scored with the Clinical Opiate Withdrawal Scale (COWS)^2,5
Onset	Within about 8 hours in one inpatient report¹
Peak and duration	Not measured for 7-OH; short-acting opioid withdrawal typically peaks at 48 to 72 hours and eases in 5 to 7 days⁶
Main treatment used	Buprenorphine or buprenorphine-naloxone; methadone in one case^1,3
Size of evidence base	A handful of single-patient case reports plus one nine-patient case series³
Biggest risk after stopping	Overdose if use restarts after tolerance has dropped^7,6
Federal status (24 Oct 2026)	Not yet scheduled; DEA order possible from 13 November 2026⁸

Why 7-OH causes physical dependence

7-hydroxymitragynine is a minor alkaloid in the kratom leaf and an active metabolite of mitragynine, the leaf’s main alkaloid. In human liver preparations, the enzyme CYP3A converts mitragynine into 7-OH, which is a much more potent mu-opioid receptor agonist than its parent compound.⁹ Receptor studies found that 7-OH binds the human mu-opioid receptor with about nine times the affinity of mitragynine and acts as a partial agonist, while mitragynine behaved as an antagonist in the same assay.¹⁰ In rats trained to recognise morphine, 7-OH was almost completely interchangeable with it.¹⁰ Our summary of kratom and opioid receptor research gives the wider background.

The FDA’s July 2025 letter to doctors cited research describing 7-OH as 13 times more potent than morphine, and listed addiction and withdrawal among its effects.¹¹ Animal work dating back to 2005 showed that mice given 7-OH repeatedly developed tolerance, cross-tolerance with morphine and naloxone-triggered withdrawal signs comparable to morphine-treated animals.¹²

The products matter as much as the molecule. Tablets, shots and sublingual films sold as “7-OH” deliver far more of the compound than leaf ever does, and some routes bypass first-pass metabolism in the liver, which speeds onset.¹³ Our explainers on mitragynine vs 7-hydroxymitragynine and how 7-OH products differ from traditional kratom cover the chemistry in more depth.

What the 2025 and 2026 case reports show

Almost everything known about 7-OH withdrawal in people comes from case reports published in 2025 and 2026. Each describes one person, often with a history of other opioid use, and none can tell us how common or how severe withdrawal typically is.

Report	Patient	What happened
Reif et al., 2025¹³	Man, 35, past heroin use	Noticed tolerance within days of starting a 7-OH film; within 2 weeks was using every 1 to 2 hours. Severe use disorder; started on buprenorphine
Hendler et al., 2026¹	Man in his 30s	Withdrawal within 8 hours of admission; stabilised with methadone over 36 hours, then switched to buprenorphine
Wightman and Hu, 2026²	Man, 38, history of opioid use disorder	Escalated from kratom to 7-OH; COWS peaked at 14 (moderate). Short buprenorphine course, then tapered off
Lybik et al., 2026¹⁴	Man, 43	Presented about 48 hours after his last dose with nausea, diarrhoea, cramps, chills and anxiety; treated in the emergency department
Held and Varicat, 2026⁵	Man, 49, admitted for depression	Had not disclosed 7-OH use; COWS rose to 24 before it was identified. Needed a larger-than-usual buprenorphine-naloxone induction
Kiyokawa et al., 2026¹⁵	Woman who had used kratom to quit illicit opioids	Moved to 7-OH, developed tolerance and suicidal thoughts; withdrawal resembled opioid withdrawal; treated with high-dose buprenorphine-naloxone
Fenske et al., 2026³	Nine telehealth patients	Buprenorphine started successfully in 8 of 9, with no precipitated withdrawal; symptoms improved at a median of 6 weeks

Two themes recur. Several patients escalated from leaf kratom to concentrated 7-OH, and 7-OH use was easy to miss: one patient did not mention it at admission, and his team only made sense of his withdrawal once he did.⁵ Routine laboratory testing may not pick up 7-OH,¹³ which is why our guide to whether kratom shows up on a drug test matters here: telling clinicians directly is often the only way they will know.

Not every case went smoothly. One patient who stopped 7-OH and high-dose nicotine pouches together deteriorated to psychosis and breathing problems needing intensive care, after a buprenorphine start triggered precipitated withdrawal.¹⁶

7-OH withdrawal symptoms

The symptoms described in the case reports overlap closely with classic opioid withdrawal.^1,2,14,16 MedlinePlus lists early opioid withdrawal as restlessness, anxiety, muscle aches, watery eyes, runny nose, sweating, yawning and trouble sleeping, followed later by stomach cramps, diarrhoea, enlarged pupils, goosebumps, nausea and vomiting.⁷

Case reports add raised heart rate and blood pressure, irritability and intense craving.^14,17 Get urgent care for vomiting or diarrhoea you cannot keep up with, confusion, chest pain, seizures or thoughts of self-harm. Low mood deserves particular attention. At least three published patients were hospitalised with depression or suicidal thoughts linked to their use.^5,15,17 If that applies to you, call or text 988, the Suicide and Crisis Lifeline.

7-OH withdrawal timeline: what is known and what is estimated

No study has tracked untreated 7-OH withdrawal from start to finish. The table combines case-report observations with the better-studied course of short-acting opioid withdrawal. It is a rough guide, not a prediction.

Phase	Typical timing (estimate)	Basis
Early symptoms	Within roughly 6 to 24 hours of the last dose	8 hours in one 7-OH case¹; 6 to 24 hours for heroin⁶
Peak	Around days 2 to 3	48 to 72 hours for heroin⁶; not measured for 7-OH
Acute phase eases	Around days 5 to 7	Heroin data⁶; in a related case, symptoms resolved over 72 to 96 hours with supportive care¹⁷
Lingering symptoms	Weeks or longer	Sleep and mood problems can persist for weeks after opioid withdrawal; craving can last longer⁶

Why the fast onset? Half-life is part of the answer. In a controlled study of kratom leaf powder, 7-OH had a mean half-life of 4.7 hours after a single dose and 24.7 hours after 15 daily doses, against 43.4 and 67.9 hours for mitragynine.¹⁸ Drugs with short half-lives are more likely to produce withdrawal or discontinuation syndromes.¹⁹ Those figures come from leaf; no equivalent data exist for concentrated 7-OH products.

7-OH withdrawal vs the kratom withdrawal timeline

Withdrawal from leaf kratom is documented in larger studies. A Malaysian survey of 293 regular users found muscle pain, poor sleep, watery eyes and nose, hot flushes, diarrhoea, restlessness and tension were common.²⁰ A 2023 expert forum concluded that kratom withdrawal is generally milder than withdrawal from frequent opioid use and is usually self-manageable, and that methadone or buprenorphine should not be first-line treatment for most people with leaf kratom withdrawal.²¹ In US kratom consumers, withdrawal and use-disorder symptoms tracked dose frequency more closely than dose size.²²

Concentrated 7-OH appears to behave differently. A 2026 case report describing withdrawal from mitragynine pseudoindoxyl, a related semi-synthetic alkaloid, put it bluntly: traditional kratom tends to produce mild, delayed withdrawal, while these derivatives can cause rapid-onset, full-spectrum opioid withdrawal.¹⁷ In practice, that means the kratom withdrawal timeline is not a safe guide for someone who has been using 7-OH tablets or shots several times a day. Our overview of how kratom tolerance develops explains the leaf side of this picture, and our research overview of 7-OH tolerance covers the concentrated products.

How clinicians have treated 7-OH withdrawal

There is no standard protocol. This is what doctors did in published cases, not a treatment plan; none of these medicines should be started without a prescriber.

Buprenorphine or buprenorphine-naloxone. The most common choice. In the nine-patient series, clinicians used low-dose initiation in six patients and standard initiation in three, with successful stabilisation in eight.³ Two reports found patients needed more buprenorphine than standard starting doses, consistent with high opioid tolerance.^5,15 One patient chose a short course and was tapered off in hospital.²
Methadone. Used to stabilise one inpatient over 36 hours before a switch to buprenorphine.¹
Non-opioid symptom relief. Emergency and inpatient teams have added clonidine, anti-sickness medicines, loperamide, muscle relaxants and simple painkillers.^14,17
Relapse prevention. In the mitragynine pseudoindoxyl case, naltrexone was started once the patient had been opioid-free long enough to avoid triggering withdrawal.¹⁷

Timing matters with buprenorphine. Starting it too soon after the last dose of another opioid can trigger sudden, severe “precipitated” withdrawal, which happened in one 7-OH case.¹⁶ That is why the pharmacists in one report advised timing buprenorphine to moderate withdrawal, and why some clinicians use low-dose initiation instead.^14,3 Reviewers also note that no controlled trial has tested buprenorphine for kratom use disorder.²³

Why tapering on your own carries risks

Many people try to cut down gradually on their own. That can ease symptoms, but self-managed 7-OH tapers have specific problems.

Product strength is unpredictable. A 2026 laboratory analysis of tablets, films and shots found frequent mismatches between labelled and actual alkaloid content, and the DEA notes that 7-OH products range from 1 mg to 700 mg.^24,8 A planned step down may turn out to be a step up.
Switching back to leaf may not be enough. Several patients had moved from leaf to 7-OH after developing tolerance or seeking stronger effects.^14,15
Tolerance falls faster than craving. Health services warn that the main danger after opioid withdrawal is overdose from using a former dose after tolerance has dropped.^7,6
Other substances complicate things. Stopping several substances at once, as in the nicotine pouch case, can make withdrawal more severe and harder to treat.¹⁶

If you do reduce on your own, tell someone you trust, keep naloxone nearby, avoid combining 7-OH with alcohol, benzodiazepines or other sedatives, and get medical help early rather than late. Our guide to kratom and drug interactions explains why mixing is risky.

What DEA scheduling could mean for people using 7-OH now

On 14 October 2026 the DEA published a revised notice of intent to temporarily place 7-OH and mitragynine pseudoindoxyl in Schedule I above a threshold: more than 1 mg per gram for solids or 1 mg per millilitre for liquids, or a mitragynine-to-7-OH ratio below 100.⁸ The temporary order cannot be published before 13 November 2026 and takes effect on publication, with no comment period. Kratom leaf and mitragynine itself are not covered, though the DEA stresses that below-threshold products have not been found safe.⁸ Our explainer on where 7-OH scheduling stands covers the threshold in detail.

Most concentrated 7-OH tablets and shots would be far above that line. Once the order is published, selling or possessing them would fall under Schedule I controls. For people who are physically dependent, the practical risk is a sudden loss of supply: unplanned withdrawal, or a turn to illicit opioids. The DEA notice itself records that toxicology samples from 7-OH cases often contained other drugs such as fentanyl, and calls co-use with sedatives a serious concern.⁸

If you use 7-OH daily, the safest time to talk to a clinician is now, before supply changes. Addiction services, including the telehealth clinic behind the nine-patient series, already treat 7-OH dependence with medication.³ Tell them the product, how often you use it and when you last did.

How people get help

SAMHSA National Helpline: 1-800-662-4357 (1-800-662-HELP). Free, confidential treatment referral, 24 hours a day, in English and Spanish.⁴
Your doctor or an addiction clinic: ask about medication for opioid use disorder.
Poison Help: 1-800-222-1222 for advice about a possible adverse reaction.²⁵
Emergency: call 911 for slowed breathing, unresponsiveness, chest pain or seizures. Naloxone fully reversed 7-OH-induced breathing suppression in a 2025 rat study, and the FDA approved the first over-the-counter naloxone nasal spray in 2023.^26,27
Crisis support: call or text 988 for suicidal thoughts.

Frequently asked questions

How long does 7-OH withdrawal last?

No study has measured it. Based on case reports and the course of short-acting opioid withdrawal, acute symptoms probably begin within a day of the last dose, peak around days 2 to 3 and ease over about a week.^1,6 Sleep problems, low mood and cravings can last for weeks. Medical treatment can shorten and soften the acute phase.

What are the most common 7oh withdrawal symptoms?

Case reports describe classic opioid withdrawal: anxiety, restlessness, sweating, chills, muscle aches, runny nose, yawning, insomnia, nausea, stomach cramps, diarrhoea and strong cravings.^1,14 Some patients also had raised heart rate and blood pressure. Low mood and suicidal thoughts appeared in at least two published cases, so mental health symptoms should be taken seriously and reported to a clinician.^5,15

Is 7-OH withdrawal worse than kratom withdrawal?

The limited evidence suggests it often is. Leaf kratom withdrawal is generally described as milder and slower than opioid withdrawal, while case reports of concentrated 7-OH and related semi-synthetic alkaloids describe faster, full opioid-type withdrawal.^17,21 Several patients had switched from leaf to 7-OH after their tolerance rose. Severity still varies from person to person.

Can buprenorphine be used for 7-OH withdrawal?

Clinicians have used it in most published cases, including a nine-patient series in which eight were successfully stabilised.³ It is a prescription medicine, and starting it at the wrong time can trigger precipitated withdrawal, so it needs a prescriber. No controlled trial has tested it for 7-OH. The SAMHSA helpline (1-800-662-4357) can help you find a provider.

What happens to people who use 7-OH if the DEA schedules it?

The DEA’s revised notice says a temporary Schedule I order for 7-OH above a set threshold could be published from 13 November 2026.⁸ Most concentrated products would then be controlled, and supply could fall quickly. People who are physically dependent risk unplanned withdrawal or turning to riskier drugs, so speaking to a clinician before that happens is the safer option.

Sources

Hendler R, Karavolis Z, Kim J, Gonzalez G. A Case of 7-Hydroxymitragynine Use Disorder Treated With Buprenorphine. J Addict Med. 2026 (published online 24 March 2026). DOI: 10.1097/ADM.0000000000001685. PMID: 41875249. pubmed.ncbi.nlm.nih.gov
Wightman RS, Hu D. A Case of 7-Hydroxymitragynine Use Requiring Inpatient Medically Managed Withdrawal. J Addict Med. 2026;20(4):416-418. DOI: 10.1097/ADM.0000000000001558. PMID: 40758956. pubmed.ncbi.nlm.nih.gov
Fenske E, Williams B, Hallock-Koppelman L, Buchheit BM. Buprenorphine for the Management of 7-Hydroxymitragynine (7-OH) Use: A Retrospective Case Series. J Addict Med. 2026. DOI: 10.1097/ADM.0000000000001723. PMID: 42225057. pubmed.ncbi.nlm.nih.gov
Substance Abuse and Mental Health Services Administration. SAMHSA’s National Helpline. samhsa.gov
Held JT, Varicat FP. 7-Hydroxymitragynine Withdrawal Treated With Buprenorphine-Naloxone. Prim Care Companion CNS Disord. 2026;28(4):26cr04232. DOI: 10.4088/PCC.26cr04232. PMID: 42664441. pubmed.ncbi.nlm.nih.gov
Drug and Alcohol Services South Australia, SA Health. Heroin withdrawal. April 2023. sahealth.sa.gov.au
MedlinePlus, US National Library of Medicine. Opiate and opioid withdrawal. Reviewed 15 May 2026. medlineplus.gov
Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I. 91 FR 65370, FR Doc. 2026-20943, Docket DEA-1570. 14 October 2026. federalregister.gov
Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, et al. 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Cent Sci. 2019;5(6):992-1001. DOI: 10.1021/acscentsci.9b00141. PMID: 31263758. pubmed.ncbi.nlm.nih.gov
Obeng S, Wilkerson JL, León F, Reeves ME, Restrepo LF, Gamez-Jimenez LR, et al. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats. J Pharmacol Exp Ther. 2021;376(3):410-427. DOI: 10.1124/jpet.120.000189. PMID: 33384303. pubmed.ncbi.nlm.nih.gov
US Food and Drug Administration. Dear Colleague letter on 7-hydroxymitragynine (7-OH), from Commissioner Martin A. Makary. 29 July 2025. fda.gov
Matsumoto K, Horie S, Takayama H, Ishikawa H, Aimi N, Ponglux D, et al. Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2005;78(1):2-7. DOI: 10.1016/j.lfs.2004.10.086. PMID: 16169018. pubmed.ncbi.nlm.nih.gov
Reif B, Adkins A, Boyer EW, Kanumuri SRR, Sharma A, Smith KE. Substance Use Disorder Following Consumption of a Novel Synthetic 7-Hydroxymitragynine Product. J Addict Med. 2025 (published online 5 November 2025). DOI: 10.1097/ADM.0000000000001603. PMID: 41189061. pubmed.ncbi.nlm.nih.gov
Lybik N, Cone B, Skelton S, Elfessi Z. Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: A case report. J Am Pharm Assoc (2003). 2026;66(3):103047. DOI: 10.1016/j.japh.2026.103047. PMID: 41690384. pubmed.ncbi.nlm.nih.gov
Kiyokawa M, Chun A, Hsia C. Managing 7-Hydroxymitragynine Use Disorder with Buprenorphine-Naloxone. Hawaii J Health Soc Welf. 2026;85(10):295-298. PMID: 42857839. pubmed.ncbi.nlm.nih.gov
Sharma A, Nair BS, Pemminati S. 7-Hydroxymitragynine and Nicotine Pouch Withdrawal Syndrome: A Case Report. Cureus. 2025;17(12):e98386. DOI: 10.7759/cureus.98386. PMID: 41487756. pubmed.ncbi.nlm.nih.gov
Stanciu CN. Severe Early-Onset Withdrawal Following Intentional Use of Mitragynine Pseudoindoxyl: A Case Report and Emerging Clinical Considerations. Cureus. 2026;18(3):e105224. DOI: 10.7759/cureus.105224. PMID: 41982589. pubmed.ncbi.nlm.nih.gov
Huestis MA, Brett MA, Bothmer J, Atallah R. Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder. Molecules. 2024;29(5):984. DOI: 10.3390/molecules29050984. PMID: 38474495. pubmed.ncbi.nlm.nih.gov
Andrade C. The Practical Importance of Half-Life in Psychopharmacology. J Clin Psychiatry. 2022;83(4):22f14584. DOI: 10.4088/JCP.22f14584. PMID: 35900254. pubmed.ncbi.nlm.nih.gov
Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132-137. DOI: 10.1016/j.drugalcdep.2014.03.017. PMID: 24698080. pubmed.ncbi.nlm.nih.gov
Henningfield JE, Chawarski MC, Garcia-Romeu A, Grundmann O, Harun N, Hassan Z, et al. Kratom withdrawal: Discussions and conclusions of a scientific expert forum. Drug Alcohol Depend Rep. 2023;7:100142. DOI: 10.1016/j.dadr.2023.100142. PMID: 37397437. pubmed.ncbi.nlm.nih.gov
Rogers JM, Weiss ST, Epstein DH, Grundmann O, Hill K, Smith KE. Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency. Drug Alcohol Depend. 2024;260:111329. DOI: 10.1016/j.drugalcdep.2024.111329. PMID: 38788532. pubmed.ncbi.nlm.nih.gov
Smith KE, Epstein DH, Weiss ST. Controversies in Assessment, Diagnosis, and Treatment of Kratom Use Disorder. Curr Psychiatry Rep. 2024;26(9):487-496. DOI: 10.1007/s11920-024-01524-1. PMID: 39134892. pubmed.ncbi.nlm.nih.gov
Gour A, Kanumuri SRR, Mukhopadhyay S, Pullman MK, León F, Cutler SJ, et al. Mislabeling and Status of Semisynthetic Kratom-Derived Products in the US Market. Drug Test Anal. 2026;18(10):1286-1295. DOI: 10.1002/dta.70122. PMID: 42448619. pubmed.ncbi.nlm.nih.gov
US Food and Drug Administration. 7-OH: Emergence of a Fourth Opioid Epidemic (Hiding in Plain Sight: 7-OH Products). Updated 12 October 2026. fda.gov
Zuarth Gonzalez JD, Ragsdale AK, Mukhopadhyay S, McCurdy CR, McMahon LR, Obeng S, et al. Mitragynine and 7-hydroxymitragynine: Bidirectional effects on breathing in rats. J Pharmacol Exp Ther. 2025;392(11):103720. DOI: 10.1016/j.jpet.2025.103720. PMID: 41106041. pubmed.ncbi.nlm.nih.gov
US Food and Drug Administration. Information about Naloxone and Nalmefene. Updated 8 August 2024. fda.gov

This article is for educational purposes only and is not medical or legal advice. Products discussed here are not intended to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.

7-OH Withdrawal: Symptoms, Timeline and How People Get Help